SAD, BAD Or DAD? Insiders See Risks Increasing In China IO Rush
This article was originally published in PharmAsia News
More than 50 biotechs in China are now developing immuno-oncology assets centered mainly on the checkpoint inhibitor PD-1, meaning the emerging and promising treatment area is quickly becoming a crowded battlefield, insiders at a recent ChinaBio partnering event cautioned.
Register for our free email digests: